CN101693112A - 一种去氧鬼臼毒素环糊精包合物、其制法及抗癌用途 - Google Patents
一种去氧鬼臼毒素环糊精包合物、其制法及抗癌用途 Download PDFInfo
- Publication number
- CN101693112A CN101693112A CN200910035978A CN200910035978A CN101693112A CN 101693112 A CN101693112 A CN 101693112A CN 200910035978 A CN200910035978 A CN 200910035978A CN 200910035978 A CN200910035978 A CN 200910035978A CN 101693112 A CN101693112 A CN 101693112A
- Authority
- CN
- China
- Prior art keywords
- dpt
- beta
- deoxypodophyllotoxin
- clathrate
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ZGLXUQQMLLIKAN-SVIJTADQSA-N deoxypodophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3C[C@@H]3[C@@H]2C(OC3)=O)=C1 ZGLXUQQMLLIKAN-SVIJTADQSA-N 0.000 title claims abstract description 120
- ZGLXUQQMLLIKAN-UHFFFAOYSA-N Deoxypicropodophyllin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3CC3C2C(OC3)=O)=C1 ZGLXUQQMLLIKAN-UHFFFAOYSA-N 0.000 title claims abstract description 119
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 229920000858 Cyclodextrin Polymers 0.000 title abstract description 9
- 150000001875 compounds Chemical class 0.000 title abstract description 8
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title abstract description 6
- 230000000259 anti-tumor effect Effects 0.000 title abstract description 4
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 11
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 13
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical group OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 claims description 5
- 238000000227 grinding Methods 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- -1 hydroxypropyl Chemical group 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000000527 Germinoma Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 201000003115 germ cell cancer Diseases 0.000 claims 1
- 230000000505 pernicious effect Effects 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 46
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 abstract description 22
- 241001465754 Metazoa Species 0.000 abstract description 14
- 229940079593 drug Drugs 0.000 abstract description 7
- 238000001727 in vivo Methods 0.000 abstract description 2
- 239000001116 FEMA 4028 Substances 0.000 abstract 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 abstract 2
- 229960004853 betadex Drugs 0.000 abstract 2
- 238000012404 In vitro experiment Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 description 31
- 238000012360 testing method Methods 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 23
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 229960005420 etoposide Drugs 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 238000011580 nude mouse model Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 241000699660 Mus musculus Species 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 238000002798 spectrophotometry method Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 3
- 208000036566 Erythroleukaemia Diseases 0.000 description 3
- 208000021841 acute erythroid leukemia Diseases 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 208000019065 cervical carcinoma Diseases 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 208000010749 gastric carcinoma Diseases 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 201000000498 stomach carcinoma Diseases 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 241001597008 Nomeidae Species 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000010413 mother solution Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 2
- 238000000634 powder X-ray diffraction Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- 229960001278 teniposide Drugs 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001495452 Podophyllum Species 0.000 description 1
- 235000010169 Podophyllum emodi Nutrition 0.000 description 1
- 241000332712 Sinopodophyllum hexandrum Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/16—Cyclodextrin; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Materials Engineering (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
样品序号 | DPT∶HP-β-CD(摩尔比) | DPT溶解度(mg/L) |
1 | 1∶0.54 | 45.8 |
样品序号 | DPT∶HP-β-CD(摩尔比) | DPT溶解度(mg/L) |
2 | 1∶0.82 | 62.5 |
3 | 1∶1.08 | 145 |
4 | 1∶1.65 | 263 |
5 | 1∶2.24 | 597 |
6 | 1∶4.06 | 882 |
7 | 1∶6.35 | 1018 |
8 | 1∶10.1 | 1142 |
9 | 1∶13.6 | 1208 |
10 | 1∶15.3 | 1247 |
样品序号 | DPT∶SBE-β-CD(摩尔比) | DPT溶解度(mg/L) |
1 | 1∶0.48 | 108 |
2 | 1∶0.72 | 182 |
3 | 1∶1.00 | 615 |
4 | 1∶2.33 | 1238 |
样品序号 | DPT∶SBE-β-CD(摩尔比) | DPT溶解度(mg/L) |
5 | 1∶3.27 | 2351 |
6 | 1∶6.42 | 5938 |
7 | 1∶8.06 | 8154 |
8 | 1∶11.9 | 9806 |
9 | 1∶13.4 | 10620 |
10 | 1∶15.6 | 11385 |
样品号 | 供试品取样量(mg) | 内含DPT的量(mg) | 完全溶解时水量(ml) | 溶解度(mg/L) |
1 | 99.5 | 10.85 | 29.0 | 374 |
样品号 | 供试品取样量(mg) | 内含DPT的量(mg) | 完全溶解时水量(ml) | 溶解度(mg/L) |
2 | 91.3 | 10.39 | 26.0 | 400 |
3 | 87.6 | 10.03 | 28.5 | 352 |
4 | 86.7 | 10.20 | 18.5 | 551 |
5 | 105.3 | 11.44 | 19.0 | 602 |
6 | 91.5 | 10.69 | 20.5 | 521 |
7 | 98.8 | 11.94 | 15.0 | 796 |
8 | 110.5 | 13.68 | 14.5 | 943 |
9 | 84.5 | 10.01 | 12.0 | 834 |
样品号 | 供试品取样量(mg) | 内含DPT的量(mg) | 完全溶解时水量(ml) | 溶解度(mg/L) |
1 | 188 | 10.90 | 14.8 | 736 |
2 | 175 | 11.06 | 13.5 | 819 |
3 | 170 | 9.42 | 13.8 | 683 |
4 | 192 | 10.33 | 6.50 | 1589 |
5 | 185 | 10.95 | 6.25 | 1752 |
6 | 198 | 9.59 | 6.35 | 1510 |
7 | 210 | 10.21 | 2.30 | 4439 |
8 | 205 | 10.70 | 2.10 | 5095 |
9 | 195 | 8.85 | 1.95 | 4538 |
组别 | 剂量mg/kg | 起始体重(g) | 起始动物数 | 终末体重(g) | 终末动物数 | 瘤重(g) | 抑瘤率(%) |
空白对照组 | - | 22.83±1.60 | 6 | 25.61±2.32 | 6 | 3.25±0.91 | - |
组别 | 剂量mg/kg | 起始体重(g) | 起始动物数 | 终末体重(g) | 终末动物数 | 瘤重(g) | 抑瘤率(%) |
Etoposide组 | 20 | 22.67±1.37 | 6 | 16.82±2.06** | 6 | 1.27±0.61** | 61.08 |
DPT高剂量组 | 8 | 22.33±1.51 | 6 | 22.55±2.50 | 6 | 1.85±0.95* | 43.08 |
DPT中剂量组 | 4 | 23.33±2.25 | 6 | 23.32±2.08 | 6 | 2.52±0.92 | 22.56 |
DPT低剂量组 | 2 | 22.50±1.38 | 6 | 25.32±2.25 | 6 | 2.94±0.68 | 9.49 |
Claims (10)
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100359780A CN101693112B (zh) | 2009-10-15 | 2009-10-15 | 一种去氧鬼臼毒素环糊精包合物、其制法及抗癌用途 |
EP10823054A EP2489351A4 (en) | 2009-10-15 | 2010-10-01 | CYCLODEXTRIN DEOXYPODOPHYLLOTOXIN INCLUSION COMPLEX, PREPARATION METHOD THEREOF, USE THEREOF FOR THE TREATMENT OF CANCER |
PCT/CN2010/077554 WO2011044824A1 (zh) | 2009-10-15 | 2010-10-01 | 一种去氧鬼臼毒素环糊精包合物、其制法及抗癌用途 |
US13/502,092 US8859527B2 (en) | 2009-10-15 | 2010-10-01 | Inclusion complex of deoxypodophyllotoxin of cyclodextrin, preparation method, use for treatment of cancer thereof |
AU2010306279A AU2010306279A1 (en) | 2009-10-15 | 2010-10-01 | Inclusion complex of deoxypodophyllotoxin of cyclodextrin, preparation method, use for treament of cancer thereof |
JP2012533469A JP5774013B2 (ja) | 2009-10-15 | 2010-10-01 | シクロデキストリンのデオキシポドフィロトキシン包接錯体、その調製法、および癌治療への使用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100359780A CN101693112B (zh) | 2009-10-15 | 2009-10-15 | 一种去氧鬼臼毒素环糊精包合物、其制法及抗癌用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101693112A true CN101693112A (zh) | 2010-04-14 |
CN101693112B CN101693112B (zh) | 2011-07-20 |
Family
ID=42092138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009100359780A Active CN101693112B (zh) | 2009-10-15 | 2009-10-15 | 一种去氧鬼臼毒素环糊精包合物、其制法及抗癌用途 |
Country Status (6)
Country | Link |
---|---|
US (1) | US8859527B2 (zh) |
EP (1) | EP2489351A4 (zh) |
JP (1) | JP5774013B2 (zh) |
CN (1) | CN101693112B (zh) |
AU (1) | AU2010306279A1 (zh) |
WO (1) | WO2011044824A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102380104A (zh) * | 2011-11-07 | 2012-03-21 | 吴葆金 | 去氧鬼臼毒素-羟丙基β-环糊精包合物的制备方法 |
CN113801129A (zh) * | 2021-09-30 | 2021-12-17 | 大连民族大学 | 一种鬼臼毒素脂质衍生物、纳米载体及其制备方法和在肿瘤治疗中的应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112516174B (zh) * | 2020-12-12 | 2022-12-02 | 烟台大学 | 一种包含海肠内脏的产品及其制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1424112A (zh) * | 2002-12-17 | 2003-06-18 | 上海医药工业研究院 | 难溶性药物的水溶性包合物及其制备方法 |
CN1879887B (zh) | 2006-05-11 | 2012-06-27 | 沈阳药科大学 | 基于水溶性环糊精聚合物的难溶性药物给药系统 |
CN101439188B (zh) * | 2008-12-15 | 2010-11-10 | 中国人民武装警察部队医学院 | 难溶性抗肿瘤药物的聚合物冻干制剂 |
-
2009
- 2009-10-15 CN CN2009100359780A patent/CN101693112B/zh active Active
-
2010
- 2010-10-01 JP JP2012533469A patent/JP5774013B2/ja active Active
- 2010-10-01 AU AU2010306279A patent/AU2010306279A1/en not_active Abandoned
- 2010-10-01 EP EP10823054A patent/EP2489351A4/en not_active Withdrawn
- 2010-10-01 US US13/502,092 patent/US8859527B2/en active Active
- 2010-10-01 WO PCT/CN2010/077554 patent/WO2011044824A1/zh active Application Filing
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102380104A (zh) * | 2011-11-07 | 2012-03-21 | 吴葆金 | 去氧鬼臼毒素-羟丙基β-环糊精包合物的制备方法 |
CN113801129A (zh) * | 2021-09-30 | 2021-12-17 | 大连民族大学 | 一种鬼臼毒素脂质衍生物、纳米载体及其制备方法和在肿瘤治疗中的应用 |
Also Published As
Publication number | Publication date |
---|---|
JP2013507401A (ja) | 2013-03-04 |
WO2011044824A1 (zh) | 2011-04-21 |
EP2489351A4 (en) | 2013-03-27 |
CN101693112B (zh) | 2011-07-20 |
US8859527B2 (en) | 2014-10-14 |
AU2010306279A1 (en) | 2012-05-31 |
EP2489351A1 (en) | 2012-08-22 |
US20120225934A1 (en) | 2012-09-06 |
JP5774013B2 (ja) | 2015-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102237234B1 (ko) | 간 표적성을 갖는 유전자/약물을 공동으로 운반하는 통합식 나노 시스템 및 이의 제조 방법 | |
CN112961188B (zh) | 一种四价铂前药苄达酸铂、其制剂及制备方法和应用 | |
CN107674210B (zh) | 三苯基膦-壳聚糖硬脂酸嫁接物载药胶束及制备与应用 | |
CN111205331B (zh) | 一种具有抗耐药性功能的抗肿瘤四价铂配合物及制备方法 | |
CN103059005B (zh) | 白杨素酰胺衍生物及其医药用途 | |
CN110882396B (zh) | 肿瘤微环境与氧化还原逐级响应性纳米递药系统的制备方法及应用 | |
CN111053911A (zh) | 还原响应型交联剂及其交联羟基药物分子的制备及应用 | |
CN101693112B (zh) | 一种去氧鬼臼毒素环糊精包合物、其制法及抗癌用途 | |
Quiñones et al. | Polyphosphazene-based nanocarriers for the release of camptothecin and epirubicin | |
CN106397544B (zh) | 环肽类化合物在制备抗肿瘤药物中的应用 | |
CN102525929A (zh) | 甘草次酸修饰的汉黄芩素脂质体制剂及其制备方法 | |
CN109675053B (zh) | 鬼臼毒素及其衍生物的靶向制剂及其制备方法 | |
CN108888774B (zh) | 一种雷公藤红素-树状大分子缀合物及其制备方法与应用 | |
CN104666247A (zh) | 肝素修饰的可断键阿霉素脂质体制剂及其制备方法 | |
CN107296962A (zh) | 化药/基因共转运功能化碳纳米管的制备方法及应用 | |
CN102731442B (zh) | 一种水溶性多烯紫杉醇化合物的制备方法及用途 | |
Xie et al. | Host–guest inclusion system of artesunate with β-cyclodextrin and its derivatives: characterization and antitumor activity | |
CN108727583A (zh) | 多臂靶向抗癌偶联物 | |
CN112641760B (zh) | 二茂铁-黄连素/吲哚美辛@葡萄糖氧化酶@透明质酸纳米药物、制备方法与应用 | |
CN108721636B (zh) | 联硒键连接的具有双重响应性的药物递送材料及其制备方法和应用 | |
CN108553649B (zh) | 一种新颖的管道结构的索拉非尼-γ-环糊精包合物及制备方法及应用 | |
CN107375940B (zh) | 以粘附因子icam-1为靶点的纳米药物制备及其应用 | |
CN108558914B (zh) | 基于生物素邻香草醛酰腙衍生物的铜配合物及其合成方法和应用 | |
WO2016078577A1 (zh) | 聚合物修饰的丹参酮i化合物或其纳米胶束、其制备方法和用途 | |
CN112457491A (zh) | 一种超支化聚酰胺-胺hpaa及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ZHEJIANG JIAFENG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: LUO HOUWEI Effective date: 20120920 Free format text: FORMER OWNER: WU BAOJIN WU CHANG Effective date: 20120920 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210009 NANJING, JIANGSU PROVINCE TO: 321000 JINHUA, ZHEJIANG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20120920 Address after: 321000 Zhejiang province Jinhua Wujiang Road No. 88 Patentee after: Zhejiang Jiafeng Pharmaceutical Co., Ltd. Address before: Luxi Gulou District of Nanjing city in Jiangsu province 210009 Camp No. 23 Building 2 Room 501 Patentee before: Luo Houwei Patentee before: Wu Baojin Patentee before: Wu Changhui |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Deoxypodophyllotoxin cyclodextrin inclusion compound, preparation method and antitumor application thereof Effective date of registration: 20150128 Granted publication date: 20110720 Pledgee: Bank of Communications Ltd Jinhua branch Pledgor: Zhejiang Jiafeng Pharmaceutical Co., Ltd. Registration number: 2015990000078 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20150626 Granted publication date: 20110720 Pledgee: Bank of Communications Ltd Jinhua branch Pledgor: Zhejiang Jiafeng Pharmaceutical Co., Ltd. Registration number: 2015990000078 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Deoxypodophyllotoxin cyclodextrin inclusion compound, preparation method and antitumor application thereof Effective date of registration: 20150629 Granted publication date: 20110720 Pledgee: Bank of Communications Ltd Jinhua branch Pledgor: Zhejiang Jiafeng Pharmaceutical Co., Ltd. Registration number: 2015990000525 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20161228 Granted publication date: 20110720 Pledgee: Bank of Communications Ltd Jinhua branch Pledgor: Jianfeng Pharm Co., Ltd., Zhejiang Registration number: 2015990000525 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model |